Integer Holdings Corp
NYSE:ITGR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Integer Holdings Corp
Inventory
Integer Holdings Corp
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Integer Holdings Corp
NYSE:ITGR
|
Inventory
$253.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
11%
|
CAGR 10-Years
0%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Inventory
$2.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Inventory
$1.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
|
Stryker Corp
NYSE:SYK
|
Inventory
$5.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Inventory
$6.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Inventory
$1.8B
|
CAGR 3-Years
27%
|
CAGR 5-Years
25%
|
CAGR 10-Years
27%
|
|
Integer Holdings Corp
Glance View
Integer Holdings Corporation, a prominent player in the medical device industry, has carved a significant niche by aligning innovation with robust manufacturing capabilities. Founded as a collaborative effort between technical ingenuity and healthcare innovation, Integer primarily engages in the design and production of medical devices and components that are instrumental for the med-tech sector. It serves a diverse clientele that ranges from large healthcare conglomerates to emerging med-tech companies. The company operates through two main segments: Medical and Non-Medical. In the Medical division, Integer excels by providing critical components used in cardiac rhythm management, neuromodulation, and vascular access. It thrives on the premise that precision in manufacturing and innovation are key to producing reliable and effective medical solutions, ensuring that they meet stringent regulatory standards. What truly propels Integer’s financial engine is its commitment to operational excellence and strategic partnerships. By integrating vertically across its production processes, Integer achieves cost efficiencies that allow it to offer competitive pricing without sacrificing quality. Moreover, the company extends its influence through strategic partnerships with prominent healthcare providers, thereby securing long-term contracts and steady revenue streams. This model is supplemented by its Non-Medical segment, where Integer provides high-reliability components for energy, military, and environmental applications. These ventures not only diversify its revenue portfolio but also bolster its resilience against market volatility. Integer’s growth narrative is underscored by a relentless focus on research and development, which facilitates continuous product enhancement and keeps it at the forefront of technological advancement in the medical device industry. Through these strategies, Integer Holdings Corporation not only sustains its market position but also expands its role as a critical enabler in the global healthcare landscape.
See Also
What is Integer Holdings Corp's Inventory?
Inventory
253.7m
USD
Based on the financial report for Dec 31, 2025, Integer Holdings Corp's Inventory amounts to 253.7m USD.
What is Integer Holdings Corp's Inventory growth rate?
Inventory CAGR 10Y
0%
Over the last year, the Inventory growth was 3%. The average annual Inventory growth rates for Integer Holdings Corp have been 7% over the past three years , 11% over the past five years .